Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19
Authors:
- 2 June 2021
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 53 (1) , 88-95
Abstract
Although COVID-19 disease primarily affects the respiratory system, it has been seen in many studies that it causes thromboembolic (TE) events in many tissues and organs. So that, to prevent TE can reduce mortality and morbidity. In this context, this study aimed to investigate the relationship between the previous use of warfarin or other new direct oral anticoagulants (OAC) and mortality in patients hospitalized with a diagnosis of COVID-19 before hospitalization. A total of 5575 patients who were diagnosed with COVID-19 were hospitalized and started treatment between March 21 and November 30, 2020 were included in the study. The primary outcome was in-hospital all-cause mortality. A retrospective cohort study design was planned. Patients were followed up until death or censoring on November 30, 2020. The candidate predictors for primary outcome should be clinically and biologically plausible, and their relationships with all-cause death should be demonstrated in previous studies. We considered all candidate predictors included in the model in accordance with these principles. The main candidate predictor was previous OAC use. The primary analysis method was to compare the time to deaths of patients using and not using previous OAC by a multivariable Cox proportional hazard model (CPHM). In the CPHM, previous OAC use was found to be associated with a significantly lower mortality risk (adjusted hazard ratio 0.62, 95% CI 0.42–0.92, p = 0.030). In hospitalized COVID-19 patients, in patients who previously used anticoagulantswas associated with lower risk of in-hospital death than in those who did not.Keywords
This publication has 20 references indexed in Scilit:
- Autopsy Findings and Venous Thromboembolism in Patients With COVID-19Annals of Internal Medicine, 2020
- Pathological evidence of pulmonary thrombotic phenomena in severe COVID‐19Journal of Thrombosis and Haemostasis, 2020
- Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forumJournal of Thrombosis and Thrombolysis, 2020
- Thrombin activation of PAR-1 contributes to microvascular stasis in mouse models of sickle cell diseaseBlood, 2020
- COVID-19: progression of disease and intravascular coagulation – present status and future perspectivesClinical Chemistry and Laboratory Medicine (CCLM), 2020
- Impact of Coronavirus disease (COVID-19) pandemic on health professionalsPakistan Journal of Medical Sciences, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Virus envelope tissue factor promotes infection in miceJournal of Thrombosis and Haemostasis, 2019
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2018
- Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in DiabetesAnnals of Internal Medicine, 2016